Loading...
•
Dec 31, 2020
Lexicon Pharmaceuticals Q4 2020 Earnings Report
Lexicon Pharmaceuticals reported Q4 2020 financial results and provided a clinical update.
Key Takeaways
Lexicon Pharmaceuticals reported a decrease in revenues for the fourth quarter of 2020, primarily due to the sale of XERMELO. The company is focusing on advancing its research and development pipeline, with key steps taken to advance LX9211 and sotagliflozin.
Patient enrollment continued in Phase 2 clinical study of LX9211 for diabetic peripheral neuropathic pain.
Patient enrollment commenced in Phase 2 clinical study of LX9211 for post-herpetic neuralgia.
Lexicon received Fast Track designation from the FDA for the development of LX9211 in diabetic peripheral neuropathic pain.
SOLOIST and SCORED Phase 3 studies achieved their primary endpoints for sotagliflozin.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Revenue by Segment
Revenue by Segment
Royalties and Other Revenue
CapyFin.com Forward Guidance
Lexicon anticipates several milestones and events in 2021, including NDA filing for sotagliflozin in heart failure and Phase 2 study results for LX9211 in diabetic peripheral neuropathic pain and post-herpetic neuralgia.
Positive Outlook
- NDA filing for sotagliflozin in heart failure.
- Active efforts to secure strategic alliance for sotagliflozin in heart failure.
- Phase 2 study results from RELIEF-DPN-1 for LX9211 in diabetic peripheral neuropathic pain.
- Phase 2 study results from RELIEF-PHN-1 for LX9211 in post-herpetic neuralgia.
- Additional publications for sotagliflozin and LX9211.